RxDoctor Payments Data

Lewis Kanengiser, MD

Internal Medicine · Santa Monica, CANPI 1124120787

Payments from drug & device makers

$2,077in general payments, 2019–2025

Across 79 payments — averaging $26.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$576
  • AbbVie$507
  • Gilead$153
  • Novartis$140
  • Lilly USA, LLC$93
  • GSK$86
  • plus $520 from 14 others

What the payments were for

  • Food & beverage$2,077100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,077 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$140,453
Medicare patients
255
Services billed
4,779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban62$63,363
MounjaroTirzepatide38$43,181
FarxigaDapagliflozin Propanediol24$31,945
RybelsusSemaglutide26$30,784
OzempicSemaglutide23$29,431
JanuviaSitagliptin Phosphate21$25,265
Repatha SureclickEvolocumab15$17,115
Praluent PenAlirocumab22$15,758
XareltoRivaroxaban20$14,975
SynthroidLevothyroxine Sodium143$12,764
Carvedilol ErCarvedilol Phosphate27$8,836
TradjentaLinagliptin16$8,265
Candesartan Cilexetil66$6,484
PaxlovidNirmatrelvir/Ritonavir52$5,541
Rosuvastatin Calcium279$5,152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$83$68,904114 claims
Novo NordiskRybelsus, Ozempic$24$60,21549 claims
Lilly USA, LLCMounjaro$93$43,18138 claims
AbbVieSynthroid$507$12,764143 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Santa Monica

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →